Association between serum lipoprotein (a) levels and major adverse cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction

Background: Our study investigated the association between circulating levels of lipoprotein (a) [Lp(a)] and the incidence of major adverse cardiovascular events (MACE). Materials and Methods: Primary percutaneous coronary intervention was conducted in 175 Chinese patients diagnosed with ST-segment elevation myocardial infarction (STEMI) and were followed prospectively for one year. Based on their serum Lp(a) levels, these patients were categorized into two groups: low Lp(a) group (<30 mg/dL) and high Lp(a) group (≥30 mg/dL). MACE was described as cardiovascular mortality/death, new onset of or worsening heart failure, coronary revascularization, non-fatal myocardial infarction, acute stent thrombosis, and serious arrhythmia. Results: One-year mortality was significantly greater in the high Lp(a) group (P=0.016). Receiver operating characteristic curve analysis identified that a value of 17.6 mg/dL of Lp(a) predicted MACE. Serum Lp(a) levels could predict MACE as shown by Multivirate Cox regression analysis (P<0.001). Kaplan-Meier MACE survival analysis showed that the risk of MACE was significantly greater among patients in the high Lp(a) group (log rank P<0.001). Conclusions: Serum levels of Lp(a) is a useful biomarker for STEMI patients undergoing percutaneous intervention and can be assessed for risk stratification in this patient population.